Caris Life Sciences, Inc. (NasdaqGS: CAI)
Health Care · Biotechnology · US
$29.70
+8.00% today · -5.0% 1Y
Caris Life Sciences, Inc. (NasdaqGS: CAI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.39B and employs 1,846 people.
Over the last twelve months the share price has lost 5.0%, trading between 14.19 and 33.65.
Tweenvest scores Caris Life Sciences, Inc. across four factors: quality 45/100, value 32/100. Its strongest factor is quality.
CAI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.39B
- Revenue (TTM)
- $989.61M
- P/E
- 80.06
- EPS
- 0.37
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $33.65
- 52-week low
- $14.19
- Avg volume (3M)
- —
- Shares outstanding
- 282.60M
- Employees
- 1,846
- Next earnings
- —
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
- ISIN
- US1421521071
- Founded
- 2008
- Listed since
- Jun 18, 2025
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kymera Therapeutics, Inc.NasdaqGM: KYMR | $9.35B | $112.40 | +4.67% |
| Protagonist Therapeutics, Inc.NasdaqGM: PTGX | $9.30B | $143.73 | +2.73% |
| Arrowhead Pharmaceuticals, Inc.NasdaqGS: ARWR | $8.86B | $62.75 | +3.31% |
| Cytokinetics, IncorporatedNasdaqGS: CYTK | $8.75B | $62.91 | +1.45% |
| Spyre Therapeutics, Inc.NasdaqGS: SYRE | $8.01B | $85.69 | -8.05% |
| TG Therapeutics, Inc.NasdaqCM: TGTX | $7.85B | $55.37 | +1.99% |
| ABIVAX Société AnonymeENXTPA: ABVX | $7.71B | €79.00 | +2.46% |
| RemeGen Co., Ltd.SEHK: 9995 | $7.56B | HK$70.40 | -3.43% |
Figures last refreshed Oct 11, 2026.